NCT01161615 is a Phase 3 clinical trial of MRX-7EAT in Acute Tendonitis, sponsored by MEDRx USA, Inc..

Who is sponsoring NCT01161615?

NCT01161615 is sponsored by MEDRx USA, Inc..

What drugs are being tested in NCT01161615?

Interventions in NCT01161615: MRX-7EAT, Placebo.

What condition does NCT01161615 study?

NCT01161615 studies Acute Tendonitis, Bursitis.

Is NCT01161615 still recruiting?

NCT01161615 is currently completed. Last updated 14 January 2018.

Last reviewed 2018-01-14 · How we verify

NCT01161615

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder

Completed Phase 3 Last updated 14 January 2018

What this trial tests

Phase 3 trial testing MRX-7EAT in Acute Tendonitis in 350 participants. Completed in 1 June 2011.

Timeline

1 July 2010

Primary endpoint
1 June 2011

1 June 2011

Quick facts

Lead sponsor	MEDRx USA, Inc.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	350
Start date	1 July 2010
Primary completion	1 June 2011
Estimated completion	1 June 2011
Sites	35 locations across United States

Drugs / interventions tested

MRX-7EAT — full drug profile →
Placebo

Conditions studied

Acute Tendonitis — all drugs for Acute Tendonitis →
Bursitis — all drugs for Bursitis →

Sponsor

MEDRx USA, Inc. — full company profile →

Who can join

14 and older, any sex, with Acute Tendonitis or Bursitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Mean of all 24 Current Pain Intensity scores collected on Days 2 through 7 on a 0-10 NPRS.
Time frame: 7 days

Sponsor's own description

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Tendonitis

Currently open trials in the same condition.

NCT06834425 — Efficacy of NSAID Peritendinous Injection for Acute Tendinitis · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01161615 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MEDRx USA, Inc.
Last refreshed: 14 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01161615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing